HER2-Positive Breast Cancer

In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?

A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.

Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.

Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.

A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.

This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.

A novel cancer vaccine targeting HER2-positive malignancies has progressed quickly from mouse trials into early-phase human trials, with promising results.

The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer.

A new laboratory study has shed some light on how mitochondrial metabolism is altered in breast cancer.

Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach.

The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis.

A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.

An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies.

Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.

The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.

The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2+ breast cancer.

Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.

New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer.

A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances.

Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer.

Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy.

Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines.

Some patients with HER2-positive breast cancer may develop an immunosuppressive phenotype based on an increase in regulatory T cells following treatment.

The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.

A trastuzumab biosimilar known as SB3 showed equivalent efficacy and safety to trastuzumab itself in a phase III trial of women with early HER2-positive breast cancer in the neoadjuvant setting.

A combined approach targeting ER, HER2, and RB1 yielded promising results in terms of Ki-67 expression in women with HER2-positive, ER-positive breast cancer.

This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.

Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2+, HR+ metastatic breast cancer.

Cardiac effects of pertuzumab and trastuzumab following chemotherapy in the neoadjuvant setting were limited for HER2-positive breast cancer patients.

Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 1 year of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer.